Immune drugmaker TRex Bio has

免疫药物制造商 TRex Bio 已

priced a $117 million initial public offering

定价1.17亿美元的首次公开募股

, joining the ranks of nearly two dozen biotechnology companies that have done so in 2026.

，加入2026年已采取此举的近二十家生物技术公司的行列。

TRex sold 8,333,334 shares at $14 each, meeting the lower end of projections it set earlier in the week

TRex 以每股 14 美元的价格售出 8,333,334 股，达到其本周早些时候设定的预测区间下限

.

。

The company begins trading Friday on the Nasdaq under the ticker symbol “TRXB.”

该公司将于周五在纳斯达克开始交易，股票代码为“TRXB”。

TRex is developing drugs that can treat diseases by calming an immune system that's become overstimulated. The company hopes to achieve this by creating medicines

TRex 正在开发能够通过平息过度激活的免疫系统来治疗疾病的药物。该公司希望通过研制药物来实现这一目标

that activate regulatory T cells, or 'Tregs,'

激活调节性T细胞（或称“Tregs”）

which guard the body from attacking itself and promote wound healing.

它们保护身体免受自身攻击，并促进伤口愈合。

TRB-061 is a fusion protein that goes after a receptor on Tregs called tumor necrosis factor receptor 2. Once it finds its target, TRB-061 is designed to help those cells spur into action and multiply, soothing inflammation in the skin and gut without broadly blunting the immune system. A Phase 1 study is underway, with topline data coming in 2027, the company said in a regulatory filing..

TRB-061 是一种融合蛋白，靶向调节性 T 细胞（Tregs）上称为肿瘤坏死因子受体 2 的受体。一旦找到靶点，TRB-061 旨在促使这些细胞激活并增殖，从而缓解皮肤和肠道的炎症，而不会广泛抑制免疫系统。该公司在一份监管文件中表示，一项 1 期临床研究正在进行中，顶线数据将于 2027 年公布。

Another drug TRex has outlined as a candidate for treating inflammatory bowel disease could enter testing next year. Called TRB-071, it's directed at a different Treg receptor, CD30, and helps both enhance Treg activity while blocking another source of inflammation. The company has

TRex公司提出的另一种用于治疗炎症性肠病的候选药物有望于明年进入试验阶段。该药物名为TRB-071，靶向另一种Treg受体CD30，既能增强Treg活性，又能阻断另一炎症来源。该公司已

partnered with Eli Lilly and Johnson & Johnson

与礼来公司和强生公司建立合作伙伴关系

to find new anti-inflammatory drugs. Both pharma companies have licensed or exercised options to develop experimental treatments discovered by TRex.

以寻找新的抗炎药物。两家制药公司已获得许可或行使选择权，以开发由TRex发现的实验性疗法。

Lilly is TRex’s largest equity owner, holding about 24% of shares in the biotech prior to its IPO. The big drugmaker also indicated interest in buying up a portion of the startup’s IPO stock. TRex has banked $220 million in venture financing to date, including a $50 million raise earlier this year to support its ongoing Phase 1 trial..

礼来公司是TRex最大的股权所有者，在该生物科技公司首次公开募股（IPO）前持有约24%的股份。这家大型制药商还表示有兴趣购买该初创公司IPO发行的部分股票。截至目前，TRex已筹集2.2亿美元的风险投资，其中包括今年早些时候为支持其正在进行的1期临床试验而完成的5000万美元融资。

Another biotech firm, Retension Pharmaceuticals, also went public on Thursday

另一家生物科技公司Retension Pharmaceuticals也于周四上市

with an upsized $45 million offering

以扩大至4,500万美元的发行规模

. These two latest deals, combined with other recent IPOs, a

. 这两笔最新交易，加上其他近期的首次公开募股（IPO），

similar number of reverse mergers

数量相近的反向并购

and a few “SPAC” deals, show how public market investment in biotechs has “accelerated at unprecedented clip in 2026,” according to a Monday report from investment firm William Blair.

以及一些“特殊目的收购公司”（SPAC）交易，显示出公共市场对生物科技公司的投资在2026年“以前所未有的速度加速”，根据投资公司William Blair周一发布的一份报告。

Of the 23 drug developers that have gone public in 2026, six, or a little over 25%, have been developing treatments for immune diseases,

在2026年上市的23家药物研发企业中，有6家（略高于25%）一直在开发针对免疫性疾病的治疗方法。

according to BioPharma Dive data

根据BioPharma Dive的数据

.

。